Study Finds No Improvement In Quality Of Life With ESAs

Erythropoietin-stimulating agents (ESAs) continue to be widely prescribed despite the absence of evidence demonstrating benefit. TREAT– the first and only large trial to test clinical outcomes with the drugs–showed that ESAs did not reduce clinical events, though it did raise concerns that the drugs might increase the risk of stroke. Critics say that the drugs...Click here to continue reading...

Source: CardioBrief - February 15, 2016 Category: Cardiology Authors: Larry Husten Tags: Diabetes Policy & Ethics Prevention, Epidemiology & Outcomes anemia chronic kidney disease CKD dialysis Erythropoietin ESAs Source Type: blogs